Mouse Lymphoma Model-Based Senescence Exploitation To Predict Treatment Outcome Of Dlbcl Patients

Introduction: Molecularly informed treatment decisions are the basis of personalized cancer precision medicine. While gene expression profiling has been used to map the molecular landscape of tumors and to study the impact of molecularly defined subtypes on treatment outcome, biological effector principles, specifically cellular senescence, remain largely understudied. Syngeneic mouse models of cancer that recapitulate core molecular features of human malignancies could serve as useful models to explore mechanisms of drug sensitivity, and, likewise, to dissect molecular mechanisms of treatment failure. In particular, we focus here on the role of therapy-induced senescence, a histone H3 lysine 9 trimethylation (H3K9me3)-governed terminal cell-cycle arrest program.